commensal-virus
(2)
Chris McNulty
Chris McNulty is the interim CEO of Ring Therapeutics, a Cambridge, Massachusetts biotech developing genetic medicines that use commensal anelloviruses as delivery vectors. An MIT-trained engineer with a Harvard MBA, he joined Ring in May 2023 as Chief Financial Officer and Head of Corporate Strategy and stepped up to lead the company in December 2024. Over more than 15 years in pharma and biotech finance, he has closed financing transactions worth more than $300 million across companies including VBI Vaccines, InVivo Therapeutics, Repligen, and Genzyme.
Tuyen Ong
Tuyen Ong is a physician-turned-biotech executive who spent four years as CEO of Ring Therapeutics, the Flagship Pioneering company trying to turn anelloviruses - harmless viruses that already live in nearly everyone - into a redosable delivery system for genetic medicines. Trained as an ophthalmologist at University College London with an MBA from NYU Stern, he built his career on gene therapy for rare eye disease at Nightstar, Biogen, PTC, Bausch & Lomb and Pfizer before betting on a virus most scientists had written off as biological junk. In 2025 he co-founded PharmasMarket, a drug-development consultancy.